In this article, we will look at the 10 Stocks That Will Make You Rich In 2025.
What to Expect from the Stock Market in 2025
Jurrien Timmer, Director of Global Macro at Fidelity Management & Research Company, recently shared his outlook for the stock market in 2025. His analysis reflects cautious optimism, emphasizing potential growth and significant risks. Timmer described 2024 as a “Goldilocks” year for U.S. stock returns, characterized by robust earnings growth and rising valuations. The S&P 500 Index experienced a substantial increase, concluding the year with a gain of approximately 28% as it reached new all-time highs. This performance was driven by strong earnings from major companies, particularly the so-called “Magnificent Seven” stocks whose growth has significantly influenced the overall market dynamics.
READ ALSO: 10 Best Entertainment Stocks To Buy According to Analysts and 11 Best Computer Hardware Stocks to Invest in Right Now.
Looking ahead to 2025, Timmer maintained a bullish stance on stocks but cautioned that investors should not expect returns to match the spectacular gains of the previous two years. He noted that while earnings forecasts remain strong, especially for the mega-cap stocks, valuations are stretched, currently sitting in the 90th percentile historically. This suggests that significant further expansion in price-to-earnings (PE) ratios could lead to a bubble scenario, which he believes is unlikely. He expects continued earnings growth to support stock prices in 2025. However, valuations may limit future growth. Timmer suggests that earnings must drive performance rather than further valuation expansion to avoid a bubble scenario.
With the bull market entering its third year, Timmer describes it as being in “later innings,” indicating increased caution regarding future performance. He also suggested several risks that could potentially impact the market in 2025. For instance, heavy reliance on a few mega-cap stocks poses a risk; if these stocks falter, it could drag down overall market performance despite broader participation from other stocks. Secondly, although he does not foresee a return to the high inflation rates of the past decades, he warns that rising inflation could lead to higher interest rates, which would negatively affect the stock market.
With that let’s take a look at the 10 stocks that will make you rich in 2025.
Our Methodology
To compile the list of 10 stocks that will make you rich in 2025, we conducted a consensus. We sifted through various internet rankings to get an initial list of stocks expected to explode in 2025. Next, we sourced analyst sentiment for each stock from CNN and ranked our list in ascending order of the analysts’ projected upside potential for the next twelve months. Please note that the data was recorded on Friday, December 20, 2024.
Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
10 Stocks That Will Make You Rich In 2025
10. TG Therapeutics, Inc. (NASDAQ:TGTX)
Analysts Upside Potential: 33.54%
TG Therapeutics, Inc. (NASDAQ:TGTX) is a biopharmaceutical company that focuses on developing and selling new treatments for diseases related to B-cells, which are a type of white blood cell important for the immune system. One of their key products is BRIUMVI, which has been approved for treating relapsing forms of multiple sclerosis in adults. This disease affects the central nervous system, causing the immune system to mistakenly attack the protective covering of nerve fibers, called myelin.
During the fiscal third quarter of 2024, TG Therapeutics, Inc. (NASDAQ:TGTX) reported strong growth for BRIUMVI. The drug generated $83.3 million in net sales, reflecting a 15% increase from the previous quarter and a staggering 230% growth year-over-year. Management noted that the uptake of BRIUMVI is exceeding expectations, driven by positive clinical data presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) annual meeting. The data showed that after five years of treatment, 92% of patients were free from disability progression.
TG Therapeutics, Inc. (NASDAQ:TGTX) is working on a subcutaneous version of BRIUMVI, which would allow for at-home administration. This new formulation is expected to open up additional market opportunities and enhance patient convenience. Moreover, management also received FDA clearance to begin studies on azer-cel, a CAR T-cell therapy for autoimmune diseases, targeting a Phase 1 study launch by early next year. Looking ahead, management has raised its full-year revenue guidance for BRIUMVI to a range of $300 million to $305 million. It is one of the 10 stocks that can make you rich in 2025.
9. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Analysts Upside Potential: 35.93%
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global leader in cystic fibrosis (CF) treatments. CF is a genetic disorder affecting the lungs and digestive system. The company has developed CFTR modulators, which are designed to correct a defective protein that causes the disease’s symptoms. The issue with CFTR modulators is that they don’t work on every CF case. However, the company developed its competitive edge with the Trikafta treatment getting approved in 2019. Trikafta can treat approximately 90% of CF patients and has been a major contributor to the company’s revenue. It generated over $9.8 billion in revenue last year with a 12% increase in product revenue to $2.77 billion in the latest quarter i.e. third quarter of fiscal 2024.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is advancing its CF treatment portfolio with a next-generation triple therapy known as Vanza. The company has submitted a New Drug Application (NDA) for Vanza, which has been accepted by the FDA with a priority review status. The target action date for approval is set for January 2, 2025. PGIM Jennison in its Q2 2024 investor letter mentioned that they expect the FDA approval for Vanza will lead to top-line and margin expansion for the company in 2025 and onwards.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 stocks that will make you rich in 2025. With that, let’s take a look at what PGIM Jennison said about Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its Q2 2024 investor letter:
“Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a commercial-stage biopharmaceutical with a core franchise of small molecule CFTR modulators for cystic fibrosis (CF), a genetic and progressively fatal respiratory disease. Vertex has built a unique and unrivaled market position as the dominant market leader in CF, having created and expanded the market into a nearly $10B franchise and growing. Later this year, we expect them to receive approval for their next-gen CF triple therapy, which we think will drive top-line growth and margin expansion in 2025 onwards. Vertex is also developing an acute and chronic pain franchise. Vertex reported positive Phase 3 data in acute pain and Phase 2 data in chronic pain earlier this year; the FDA filing in acute pain has been completed, and pending approval, Vertex expects to launch in acute pain in early 2025. Beyond CF and pain, Vertex has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit. It currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, APOL-1 kidney disease, IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. Vertex has had a strong start to the year and has delivered positively on several clinical trial readouts, as well as beat Q1 revenue estimates and maintained what was a better than expected ’24 guidance. Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain.”
8. MercadoLibre, Inc. (NASDAQ:MELI)
Analysts Upside Potential: 35.96%
MercadoLibre, Inc. (NASDAQ:MELI) is a leading e-commerce platform in Latin America. It operates through two main segments: e-commerce and Fintech. It was founded in 1999 and quickly established its competitive first-mover advantage by developing an extensive logistics network across the region. It now operates in 18 countries with most of its revenue coming from Brazil, Mexico, and Argentina. Management quickly developed another strategic advantage by introducing Mercado Pago’s digital payments platform for its shoppers, which later became the foundation of its Fintech segment.
The company reported robust financial performance in the third quarter of 2024. It achieved 34% year-over-year growth in gross merchandise volume (GMV) in Brazil and 27% growth in Mexico. Moreover, in Argentina the number of items sold grew by 16%, surpassing 60 million items sold, marking the highest volume ever for the platform. The company added nearly 7 million new buyers, a figure that exceeds even the peak growth seen during the pandemic.
Despite these impressive growth figures e-commerce penetration in Latin America remains low, with only 15% of commerce occurring online. According to Parnassus Growth Equity Fund, the low online commerce penetration figures in Latin America present a long runway of growth for MercadoLibre, Inc. (NASDAQ:MELI). Considering its brand presence and robust logistics network throughout the region the company is expected to benefit from shoppers transitioning from offline to online mode of shopping. Here’s what Parnassus Growth Equity Fund stated regarding MercadoLibre, Inc. (NASDAQ:MELI) in its Q3 2024 investor letter:
“Against the backdrop of macro uncertainty, we opportunistically added high-quality businesses that had sold off amid overstated fears of consumer spending weakness. These new holdings include fast-casual chain Chipotle Mexican Grill and Latin American online retail giant MercadoLibre, Inc. (NASDAQ:MELI) in the Consumer Discretionary sector.
MercadoLibre benefits from the ongoing transition from offline to online shopping, along with the growing adoption of digital financial services in Latin America. With its strong brand, robust logistics network, dominant market share, and top-tier management team, the company is well positioned to sustain revenue growth and margin expansion.”
7. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Analysts Upside Potential: 47.86%
Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company that specializes in creating drugs that adjust how cortisol affects the body. Cortisol is a hormone that plays a crucial role in various bodily functions, but too much of it can lead to serious health issues. Its main product is Korlym (mifepristone), which is approved by the FDA for treating Cushing’s syndrome, a condition caused by excess cortisol.
During the fiscal third quarter of 2024, the company continued to add prescribers and more patients for Korlym. This resulted in its revenue growing 48% year-over-year to reach $182.5 million. Management noted that there is a rising awareness among physicians about hypercortisolism, leading to more screenings and treatments for affected patients. This shift is critical as it allows more individuals to receive necessary care. In addition to Korlym, Corcept Therapeutics Incorporated (NASDAQ:CORT) is preparing to submit a New Drug Application (NDA) for Relacorilant, by the end of the year. Relacorilant is a medication that also treats people with Cushing’s syndrome.
As the company anticipated approval for its Cushing syndrome, management has raised its full-year guidance for 2024. It now expects revenue in the range of $675 million and $700 million. ClearBridge Small Cap Value Strategy indicated an attractive growth runway for Corcept Therapeutics Incorporated (NASDAQ:CORT) considering the likelihood of FDA approval. Here’s what ClearBridge Small Cap Value Strategy stated regarding Corcept Therapeutics Incorporated (NASDAQ:CORT) in its Q2 2024 investor letter:
“Health care results lifted relative performance during the period and included our top two individual performers in Lantheus and newer portfolio addition Corcept Therapeutics Incorporated (NASDAQ:CORT). Corcept, which was added last quarter, announced that it had successfully reached its main goal in its Phase 3 trial for its treatment for patients with Cushing’s syndrome. We believe the new drug’s efficacy and safety significantly increases its likelihood of approval and offers an attractive growth runway via possible extension into other indications.”
6. Uber Technologies, Inc. (NYSE:UBER)
Analysts Upside Potential: 48.20%
Uber Technologies, Inc. (NYSE:UBER) is a technology company that operates a platform connecting users with various services including ride-sharing, food delivery, grocery, public transport integration, and freight services. The company operates in around 70 countries across the globe. Although the stock has dropped 12.70% over the past 6 months, its investment case remains robust and it ranks 6th on our list of stocks that will make you rich in 2025.
Goldman Sachs recently placed Uber Technologies, Inc. (NYSE:UBER) as one of its top picks for 2025 and analyst Eric Sheridan noted that the company’s risk-to-reward balance remains one of the most attractive ones going into 2025. He mentioned that the price fluctuation is merely due to the short-term debates concerning the rise of autonomous vehicles and its impact on mobility growth. However, Sheridan highlighted that he is more focused on the company’s long-term performance and its delivery regarding February 2024 Investor Day commitments.
Uber Technologies, Inc. (NYSE:UBER) performed well during the fiscal third quarter of 2024. It achieved a 20% year-on-year increase in gross bookings when adjusted for constant currency, reaching approximately $41 billion during the quarter. It also generated an all-time high GAAP operating profit of over $1 billion, marking a substantial milestone in its financial trajectory. In addition, the company now boasts over 161 million monthly active users, with a notable increase in trip frequency. Moreover, to tackle any potential threats from the rise of autonomous vehicles, management is collaborating with 14 partners to enhance deployment plans for autonomous technology, which is expected to add significant value to their operations.
RiverPark Large Growth Fund stated the following regarding Uber Technologies, Inc. (NYSE:UBER) in its first quarter 2024 investor letter:
“Uber Technologies, Inc. (NYSE:UBER): UBER was a top contributor in the quarter following better than expected 4Q23 earnings and 1Q24 guidance. Gross bookings of $37.6 billion were up 22% year over year. Mobility gross bookings of $19.3 billion grew 29% over last year driven by a combination of product innovation and driver availability. Delivery gross bookings of $17 billion were up 19% from last year and continued to be strong throughout the quarter. 4Q Adjusted EBITDA of $1.3 billion, up $618 million year over year, was better than management’s guidance of $1.2 billion, and the company generated $768 million of free cash flow, up from a cash loss of $303 million last year. Management guided to continuing growth in 1Q Gross Bookings (20% growth) and Adjusted EBITDA (of $1.3 billion). The company hosted a well-received analyst day in February during which it guided to three year compounded annual growth rates for gross bookings of mid-to-high single digits and EBITDA of 30-40%, both above investor expectations. The company also guided to free cash flow conversion of 90% of EBITDA.
UBER remains the undisputed global leader in ride sharing, with a greater than 50% share in every major region in which it operates. The company is also a leader in food delivery, where it is number one or two in the more than 25 countries in which it operates. Moreover, after a history of losses, the company is now profitable, delivering expanding margins and substantial free cash flow. We view UBER as more than a ride sharing and food delivery service; we also see it as a global mobility platform with 142 million users (by comparison, Amazon Prime has 200 million members) and the ability to penetrate new markets of on-demand services, such as package and grocery delivery, travel, and hourly worker staffing. Given its $5.4 billion of unrestricted cash and $4.8 billion of investments, the company today has an enterprise value of $165 billion, indicating that UBER trades at 21x our estimates of next year’s free cash flow.”
5. Nu Holdings Ltd. (NYSE:NU)
Analysts Upside Potential: 49.33%
Nu Holdings Ltd. (NYSE:NU) is a Brazilian company that operates primarily as a digital bank through its platform, Nubank. The company provides various financial services including credit and debit cards, interest earnings accounts, investment products, loans, and insurance options. It has two strategic moats over its competitors. The first is its entirely online operations which helps keep costs low and allows it to offer services at reduced fees compared to traditional banks. The second edge is its special focus on Latin America which has limited access to banking services.
Nu Holdings Ltd. (NYSE:NU) has been focused on three main principles namely customer growth, increasing revenue per customer, and efficient operating costs. During the fiscal third quarter of 2024, the company achieved a total of 110 million customers globally, marking a 56% increase from 70 million two years ago. This growth is primarily driven by strong additions in Brazil, where they added an average of 1.1 million new customers each month, reaching nearly 99 million customers. Moreover, the company also added 1.2 million customers in Mexico, bringing the total to 8.9 million.
Financially speaking the bank generated revenues of $2.9 billion, reflecting a 56% year-over-year increase. This growth was fueled by successful cross-selling and up-selling strategies, as well as new product introductions. Some of its recent new product launches include NuCel, a mobile phone service in Brazil, aimed at simplifying telecommunications for customers. It is also developing a marketplace platform that allows customers to access various products and services directly through its app and is venturing into the travel sector.
Here’s what Baron FinTech Fund stated regarding Nu Holdings Ltd. (NYSE:NU) in its first quarter 2024 investor letter:
“Nu Holdings Ltd. (NYSE:NU) is a digital bank with operations in Brazil, Mexico, and Colombia. Shares appreciated during the quarter after the company reported strong balance sheet growth and improving margins. New product launches and expansion in newer countries are yielding favorable results. Nu also benefited from inclusion in the MSCI Brazil Index, which prompted buying from passively managed funds. We continue to own the stock because Nu is disrupting the financial services industry in Latin America with its digital distribution and intense focus on user experience. The company has grown to serve over 90 million customers in less than 10 years, largely through word-of-mouth referrals. We believe the company’s superior product offering will drive continued share gains in large and growing markets. “
4. Monolithic Power Systems, Inc. (NASDAQ:MPWR)
Analysts Upside Potential: 50.62%
Monolithic Power Systems, Inc. (NASDAQ:MPWR) specializes in creating power management solutions for various electronic devices. The company does not manufacture its own chips instead, it designs and develops semiconductor products and partners with other companies including NVIDIA to produce them. Its semiconductor-based power electronic solutions are used as a powerhouse for various AI chips.
ClearBridge SMID Cap Growth Strategy in its Q2 2024 investor letter mentioned Monolithic Power Systems, Inc. (NASDAQ:MPWR) to be one of the top individual contributors to its portfolio. The firm showed confidence that strong demand for AI and data center components can drive MPWR performance higher. The anticipation stood true as the company delivered record quarterly revenue of $620.1 million, representing a 22% increase compared to the previous quarter and a 30% increase from the same quarter last year. Its Enterprise Data segment which deals with providing power management solutions specifically tailored for data centers and computing environments grew more than 86% year-over-year to reach $184.5 million. In addition, the Communication Segment also experienced a remarkable 65% increase in revenue compared to the prior quarter, attributed to new product introductions in Wi-Fi, optical networking, and router solutions. It is one of the best 10 stocks that will make you rich in 2025.
ClearBridge SMID Cap Growth Strategy stated the following regarding Monolithic Power Systems, Inc. (NASDAQ:MPWR) in its Q2 2024 investor letter:
“Another top individual contributor was Monolithic Power Systems, Inc. (NASDAQ:MPWR), in the IT sector, which makes semiconductor-based power electronics for the computing and storage, automotive, industrial, communications, and consumer markets. Continued demand for AI-related companies and beneficiaries and anticipation of greater demand for data center components such as power management hardware for CPUs helped drive strong performance in the quarter. We believe Monolithic is one of the most attractive semiconductor plays within the SMID universe and that the company will continue to gain share in analog semiconductors as it wins design contracts.”
3. Celsius Holdings, Inc. (NASDAQ:CELH)
Analysts Upside Potential: 62.90%
Celsius Holdings, Inc. (NASDAQ:CELH) creates and sells energy drinks designed to support fitness and healthy lifestyles. Their main product, CELSIUS, is marketed as a drink that helps boost metabolism and burn fat, especially when combined with exercise. The company floated a new narrative of sugar-free energy drinks to target fitness influencers, athletes, and women. This narrative turned out to be one of the strategic edges for the company as according to Mordor Intelligence around 41% of overall energy drinks in the United States were sugar-free in 2022 and the company generated more than $1.31 billion in annualized revenue in 2023 marking a 101.65% increase from the previous year.
Celsius Holdings, Inc. (NASDAQ:CELH) had a tough fiscal third quarter for 2024 with revenue decreasing 31% year-over-year to $265.7 million due to distributor inventory optimization. However, management expects growth next year as it pursues growth strategies that extend beyond North America, focusing on international expansion and increasing the frequency of product consumption. The company in October launched its products in Australia and New Zealand, marking a significant step in its global expansion efforts. Earlier this year in April management had also announced plans to expand to France.
To ensure smooth expansion Celsius Holdings, Inc. (NASDAQ:CELH) has established distribution agreements with major companies like PepsiCo in Canada and Suntory Beverage & Food in the UK and Ireland. It has also acquired Big Beverage, a co-packer that will enhance its innovation capabilities and provide better control over its supply chain. Considering its expansion strategy Celsius Holdings, Inc. (NASDAQ:CELH) is one of the best stocks that will make you rich in 2025.
Carillon Eagle Mid Cap Growth Fund stated the following regarding Celsius Holdings, Inc. (NASDAQ:CELH) in its Q3 2024 investor letter:
“Celsius Holdings, Inc. (NASDAQ:CELH) develops, markets, sells and distributes functional fitness and lifestyle beverages. The stock suffered as revenue growth slowed more than expected. A leading soft-drink distributor further reduced its levels of Celsius inventory, which negatively impacted sales. Additionally, there has been a slowdown in traffic across the broader convenience store space.”
2. Chord Energy Corporation (NASDAQ:CHRD)
Analysts Upside Potential: 64.67%
Chord Energy Corporation (NASDAQ:CHRD) is an independent company that focuses on exploring and producing oil and natural gas. It primarily operates in the Williston Basin, which spans parts of North Dakota and Montana. This area is known for its rich deposits of oil and gas, particularly in formations called the Middle Bakken and Three Forks. On March 31, the company reported completing its merger with Enerplus Corporation, creating a leading exploration and production (E&P) company focused on the Williston Basin. The newly formed company boasts a substantial land position of about 1.3 million net acres in the area. The combined entity expects to achieve over $200 million in annual synergies, exceeding initial estimates.
During the fiscal third quarter of 2024, Chord Energy Corporation (NASDAQ:CHRD) reported strong financial and operational results. Oil production for the company reached 158.8 thousand barrels per day (MBopd), close to the upper limit of its guidance, and total production was 280.8 thousand barrels of oil equivalent per day (MBoepd), which also exceeded expectations. As a result total revenue of approximately $1.45 billion increased 38% year-over-year, generating $225.3 million as net income. It is one of the 10 stocks that can make you rich in 2025.
Carillon Tower Advisers stated the following about Chord Energy Corporation (NASDAQ:CHRD) in its Q3 2024 investment letter:
“Chord Energy Corporation (NASDAQ:CHRD) is an independent exploration and production company with operations in the Williston Basin in North Dakota, Montana, and South Dakota. The company’s shares lagged largely due to the recent pressure on the price of oil. Some recent data indicating slightly disappointing initial well productivity from a handful of recently completed wells also contributed to lackluster performance. Despite this, we remain optimistic about management’s ability to drive operational efficiencies following the recent close of Chord’s acquisition of Enerplus, by applying best practices of both independent companies in a manner that should provide upside to the previously communicated synergies. We believe the continued successful implementation of Chord’s 3-mile lateral strategy, which entails drilling both vertically and horizontally for distances longer than in 2-mile lateral wells, also could drive increased shareholder returns.”
1. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Analysts Upside Potential: 160.36%
Viking Therapeutics, Inc. (NASDAQ:VKTX) is a biopharmaceutical company that is currently in the clinical stage of developing new treatments for metabolic and endocrine disorders. The company is currently developing a promising weight management drug called VK2735, which targets the same receptors as Eli Lilly’s successful drug, Tirzepatide. VK2735 is a dual agonist that activates both GLP-1 and GIP receptors, which are involved in regulating appetite and glucose metabolism, making it a candidate for treating obesity.
Tirzepatide by Eli Lilly was approved by the FDA for diabetes treatment in 2022 and later for weight management in 2023. It generated substantial sales, reaching $11 billion in the first nine months of 2024, indicating a strong market demand for effective weight management solutions. The drug under development by Viking Therapeutics, Inc. (NASDAQ:VKTX) has shown promising results with Phase 1 trial patients taking the highest dose (100 mg) losing an average of 8.2% of their body weight after four weeks, which was significantly better than the placebo group (6.8% reduction).
The positive results from VK2735’s clinical trials have led to a significant increase in the company’s stock value, reflecting investor confidence in its potential to capture a large share of the market for dual receptor agonists. Alger Mid Cap Focus Fund in its second quarter investor letter stated that one-third of the US adults suffer from obesity and they believe that Viking Therapeutics, Inc.’s (NASDAQ:VKTX) upcoming drug has the potential to address a large market. Moreover, researchers at Goldman Sachs predict that the market for these drugs may reach $130 billion by 2030. It is the top stock that can make you rich in 2025.
Alger Mid Cap Focus Fund stated the following regarding Viking Therapeutics, Inc. (NASDAQ:VKTX) in its Q2 2024 investor letter:
“Viking Therapeutics, Inc. (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients suffering from metabolic and endocrine disorders. Their lead drug VK2809, a beta-selective thyroid hormone receptor agonist, is in development for nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. Their VK2735 drug is a GLP-1 dual agonist being developed for patients with obesity. During the quarter, the company’s shares were negatively impacted by several factors: 1) a challenging environment for biotechnology stocks, exacerbated by Fed policy decisions to maintain elevated interest rates, 2) increased competition in the obesity treatment landscape, 3) manufacturability and scalability concerns regarding Viking’s obesity drug and 4) the absence of strategic partnerships from large pharmaceutical companies. Despite the challenging quarter, we continue to believe that the company’s GLP-1 drug has the potential to be a best-in-class obesity drug given its favorable efficacy and safety profile. Further, with approximately one-third of U.S. adults suffering from obesity, we believe the company’s GLP[1]1 drug has the potential to address a large market once approved.”
While we acknowledge the potential of Viking Therapeutics, Inc. (NASDAQ:VKTX) to grow, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VKTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure. None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.